Hydroxyurea Dosing in Sickle Cell Disease with Renal Impairment

Introduction to Hydroxyurea Therapy

• The American Society of Hematology suggests combination therapy with hydroxyurea and erythropoiesis-stimulating agents for SCD patients with chronic kidney disease and worsening anemia 1, 2

Monitoring and Dosing Recommendations

• For patients receiving combination therapy with erythropoiesis-stimulating agents, hemoglobin levels should not exceed 10 g/dL to reduce the risk of vaso-occlusive complications 2
• Bone marrow suppression (decreased counts in one or more cell lines) is common with hydroxyurea therapy and requires temporary discontinuation if severe 3